Terms ending in 2040
Every in-force patent on CureVac AG's record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,739,335 | Nucleic Acids Encoding CRISPR-Associated Proteins and Uses Thereof In force · High confidence | Curevac SE | In force | High confidence | |
| US 12,618,060 | Novel Nucleic Acid Molecules In force · High confidence | Curevac SE | In force | High confidence | |
| US 11,723,967 | Zika Virus Vaccine In force · High confidence | Sanofi R&D Vaccins | In force | High confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
2 of these are in force and held by CureVac AG.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.